Dr. John Restaino, practiced reconstructive surgery of the foot and ankle from 1980 to 1990, and has practiced at the law since 1991. In addition to his medical and law degrees, Dr. Restaino obtained a Master of Public Health from the Division of Epidemiology at the Johns Hopkins School of Public Health in 2008. In addition to his active practice of law, Dr. Restaino is an (Adjunct) Associate Professor at the University of South Carolina (USC) College of Pharmacy where he is actively involved in pharmacoepidemiology and pharmacovigilance. Furthermore, he is a faculty member at USC's Center of Economic Excellence for Medication Safety, the Southern Network on Adverse Reactions (SONAR) and the Doris Levkoff Meddin Center for Medication Safety at the Medical University of South Carolina. Dr. Restaino has been, or is, the chair or co-chair of the Expert & Science Committees of numerous federal MDLs dating back to the Diet Pill MDL and is currently involved in the evaluation of stomach, esophageal and liver cancer because of long-term exposure to the proton pump inhibitors. Dr. Restaino has met with experts in the United States and Europe regarding this association. Dr. Restaino has assisted in the development the science and experts from across the world in many of the mass tort litigations since 1991. In addition, he has successfully defended experts under Daubert while successfully challenging defense experts. Dr. Restaino has been involved in multiple mass tort trials including those involving Rezulin, PPA and Vioxx. Dr. Restaino is asked to lecture across the country at both medical and legal programs. Dr. Restaino has also been a guest lecturer at both law schools and medical schools including the University of South Carolina, Harvard and Johns Hopkins. Dr. Restaino has published peer-reviewed medical articles in addition to legal articles and written chapters in pharmaceutical law textbooks.